TW202308654A - 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 - Google Patents

19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 Download PDF

Info

Publication number
TW202308654A
TW202308654A TW111116469A TW111116469A TW202308654A TW 202308654 A TW202308654 A TW 202308654A TW 111116469 A TW111116469 A TW 111116469A TW 111116469 A TW111116469 A TW 111116469A TW 202308654 A TW202308654 A TW 202308654A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
anxiety
ham
Prior art date
Application number
TW111116469A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 阿爾方索 雷舍
詹姆士 多赫提
杰佛瑞 馬丁 強納斯
史帝芬 傑 凱恩思
布魯斯 漢丹 剛杜斯
海倫 科昆皇
萊恩 阿諾德
維傑爾 邦沙帕利
喬伊 麗莎 鄧巴
班邦 慎諾雅吉 愛帝維加雅
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202308654A publication Critical patent/TW202308654A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111116469A 2021-04-29 2022-04-29 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 TW202308654A (zh)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US63/181,743 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US63/197,025 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US63/210,810 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US63/239,096 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US63/285,812 2021-12-03
US202163289520P 2021-12-14 2021-12-14
US202163289506P 2021-12-14 2021-12-14
US63/289,506 2021-12-14
US63/289,520 2021-12-14
US202263298601P 2022-01-11 2022-01-11
US63/298,601 2022-01-11

Publications (1)

Publication Number Publication Date
TW202308654A true TW202308654A (zh) 2023-03-01

Family

ID=81748925

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111116469A TW202308654A (zh) 2021-04-29 2022-04-29 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法

Country Status (11)

Country Link
US (1) US20240216395A1 (https=)
EP (1) EP4329770A1 (https=)
JP (2) JP2024515829A (https=)
KR (1) KR20240006026A (https=)
AU (1) AU2022266680A1 (https=)
BR (1) BR112023022264A2 (https=)
CA (1) CA3218072A1 (https=)
IL (1) IL307991A (https=)
MX (1) MX2023012727A (https=)
TW (1) TW202308654A (https=)
WO (1) WO2022232504A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
MX2021006985A (es) * 2018-12-14 2021-09-08 Praxis Prec Medicines Inc Metodos para el tratamiento de la depresión.
KR20230041049A (ko) 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
IL315023A (en) * 2022-02-16 2024-10-01 Sage Therapeutics Inc Neuroactive steroids for treatment of cns-related disorders

Also Published As

Publication number Publication date
JP2024515829A (ja) 2024-04-10
US20240216395A1 (en) 2024-07-04
MX2023012727A (es) 2023-11-08
KR20240006026A (ko) 2024-01-12
IL307991A (en) 2023-12-01
WO2022232504A1 (en) 2022-11-03
JP2025111701A (ja) 2025-07-30
CA3218072A1 (en) 2022-11-03
BR112023022264A2 (pt) 2024-01-23
EP4329770A1 (en) 2024-03-06
AU2022266680A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
TW202308654A (zh) 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法
US20250339447A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US10278977B2 (en) Methods for treating hypersomnolence
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
RU2851101C2 (ru) 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine